osimertinib
astrazeneca
['impact,(-impacte),(-impacti),(-impactf)', 'lcsm,(-blcsm)']
#esmo22 overall, the dfs benefit is strong but there is evidence of a waning effect. are we preventing or simply delaying recurrence? how will this impact survival? great perspective from - the best in the business. #lcsm 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him